Lucence

Lucence is a precision oncology company founded in 2016, focused on advanced liquid biopsy blood tests for early cancer detection and personalized treatment selection. Headquartered in Singapore and Palo Alto, California, with additional offices in Hong Kong and Suzhou, Lucence operates CLIA-licensed, CAP-accredited, and ISO15189-certified laboratories in the US and Singapore. The company has raised over USD 75 million in funding and has a team of 73 professionals. Lucence offers a range of innovative products and services, including its flagship LiquidHALLMARK® test, which profiles 80 genes across more than 15 cancer types. The LucenceINSIGHT® test provides multi-cancer early detection with high specificity for individuals over 40. The company utilizes non-invasive technologies, such as its proprietary AmpliMARK™ platform, to analyze circulating tumor DNA and RNA from a single blood draw, enabling faster results than traditional tissue biopsies. Lucence collaborates with various global partners to expand its reach and enhance its diagnostic services.